Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is West Pharmaceutical Services Cash-to-Debt?
West Pharmaceutical ServicesWST -0.15%94 Cash-to-Debt is 1.38 as of Jun. 2026, which is 14% below its 10-year median of 1.60. GuruFocus rates WST with a GF Score™ of 94/100 and a GF Value™ of $358.55 (Fairly Valued). The stock has 9 warning signs investors should review. Among 842 Medical Devices & Instruments companies, West Pharmaceutical Services ranks worse than 52.85% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. West Pharmaceutical Services's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.38.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, West Pharmaceutical Servicescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for West Pharmaceutical Services's Cash-to-Debt or its related term are showing as below:
WST'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.74 Med: 1.6 Max: 2.93
Current: 1.4
During the past 13 years, West Pharmaceutical Services's highest Cash to Debt Ratio was 2.93. The lowest was 0.74. And the median was 1.60.
WST's Cash-to-Debt is ranked worse than 52.85% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs WST: 1.40
West Pharmaceutical Services (NYSE:WST) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
West Pharmaceutical Services Cash-to-Debt Related Terms
West Pharmaceutical Services Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services (WST) has a Cash-to-Debt of 1.38 as of Jun. 2026. This is 14% below median its historical median of 1.60. Over the past decade, West Pharmaceutical Services' Cash-to-Debt has ranged from 0.74 to 2.93. According to the industry distribution chart, West Pharmaceutical Services ranks #445 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 52.9%.
Is West Pharmaceutical Services' Cash-to-Debt too high?
West Pharmaceutical Services' current Cash-to-Debt of 1.38 is 14% below median its 10-year median of 1.60. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 2.93. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. West Pharmaceutical Services' value of 1.38 is 15.6% below this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #445 out of 842 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, West Pharmaceutical Services has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Cash-to-Debt compare to MDLN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #445 out of 842 companies for Cash-to-Debt. This places West Pharmaceutical Services in the lower half of its industry. The industry median Cash-to-Debt is 1.64. West Pharmaceutical Services' value of 1.38 is 15.6% below this benchmark. Historically, West Pharmaceutical Services' own Cash-to-Debt has ranged from 0.74 to 2.93 over the past decade. While the company's 10-year median is 1.60 vs. the industry median of 1.64, West Pharmaceutical Services has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current Cash-to-Debt of 1.38 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current Cash-to-Debt is 1.38, which is 14% below median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $358.55, compared to a current price of $361.78 — trading 0.9% above its estimated fair value. The current Cash-to-Debt is 1.38, which is 14% below median its 10-year median of 1.60 and 15.6% below the Medical Devices & Instruments industry median of 1.64. West Pharmaceutical Services' overall GF Score™ is 94/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Cash-to-Debt is 1.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be overvalued.
The current stock price of $361.78 is trading 0.9% above its estimated GF Value™ of $358.55.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
Cash-to-Debt: 1.38 (14% below median its 10-year median of 1.60)
GF Value™: $358.55 vs. price of $361.78 (0.9% above fair value)
Industry Position: 15.6% below the Medical Devices & Instruments median (#445 of 842)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
94GF Score
Get the complete analysis for WST
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
